Early Access — free while we kick the tires
EdgarHawk

LaBrosse Nicole

SVP, CHIEF FINANCIAL OFFICER

Officer
2 filings analyzed · 1 company · Latest 2025-09-11

Companies

Company Buys Sells Direction
HALOZYME THERAPEUTICS, INC. HALO 0 10 Net selling

Activity

September 2025
medium
Sell
20,000 shares
$1,514,267
Significance 5/10

HALO CFO Nicole LaBrosse sold 20,000 shares (45.1% of holdings) for $1,514,267.12 at blended avg $75.71; stock now at $77.53, up 21.1% in 30d

Nicole LaBrosse, SVP and Chief Financial Officer, executed 2 separate sales totaling 20,000 shares for $1,514,267.12 on 2025-09-10, reducing her holdings from 44.3K to 24.3K shares (a 45.1% reduction). The sales occurred at a blended average price of $75.71, below the current price of $77.53. Her prior 3 sales at HALO occurred on consecutive days in late June 2024, all of which saw positive 90-day returns (ranging from +7.6% to +9.4%), indicating those sales were not well-timed to subsequent price declines. The stock has appreciated 21.1% in the 30 days since this transaction and 43.6% over 90 days, suggesting the stock continued upward after the sale. Fundamentals show solid execution with FY revenue growth of 22.4%, a favorable P/E of 16.29, and net income of $165.2M on quarterly revenue of $325.7M.

June 2024
high
Sell
30,000 shares
$1,557,940
Significance 6/10

CFO Nicole LaBrosse sold 30,000 shares of HALO across 3 transactions (June 26-28) for $1.6M at blended average $51.93, reducing holdings by 66.0%.

Nicole LaBrosse, SVP and Chief Financial Officer, executed 3 separate sales totaling 30,000 shares for $1,557,940.00 at prices ranging from $51.82 to $52.04 over three consecutive trading days. This sale reduced her holdings from 45,480 shares to 15,480 shares, representing a 66.0% reduction in her position. The timing of this large reduction—executed as the stock trades near its 52-week high of $52.40—occurs in the context of strong recent price momentum (22.4% gain over 30 days, 28.7% over 90 days) and solid fundamentals (25.6% annual revenue growth, $195.9M latest quarterly revenue, positive net income of $76.8M). The substantial size and pace of the liquidation warrant investor attention given the CFO's fiduciary knowledge of the company's financial condition.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access